What is the recommended management for thalassemia?

Management of Thalassemia

For transfusion-dependent thalassemia major, initiate regular blood transfusions to maintain pre-transfusion hemoglobin ≥9-10 g/dL, combined with lifelong iron chelation therapy, while pursuing hematopoietic stem cell transplantation (HSCT) as early as possible in young patients with an HLA-matched sibling donor to achieve cure before iron-related organ damage develops. 1

Curative Therapy: HSCT as First-Line for Eligible Patients

HSCT should be performed as soon as possible after diagnosis in transfusion-dependent patients who have an HLA-identical sibling donor or well-matched related/unrelated donor 1. The critical principle is early intervention before iron overload causes organ dysfunction.

Optimal Timing and Patient Selection

• Age <14 years yields superior outcomes: 96% disease-free survival vs. 82% in older patients 1
• Transplant-related mortality has fallen to ≤5% in young, low-risk children with matched sibling donors 1
• Patient status at transplantation is the single most critical predictor of outcome—the Pesaro risk classification identifies three risk factors (hepatomegaly, portal fibrosis, inadequate chelation) that stratify patients into risk classes 1

Key Pitfall to Avoid

Do not delay HSCT to "optimize" the patient with years of transfusion therapy—this paradoxically worsens outcomes by allowing iron accumulation and organ damage. The goal is transplantation before complications develop, not after 1.

Donor Selection Algorithm

1. First choice: HLA-matched sibling donor (91% overall survival, 83% disease-free survival) 1
2. Second choice: Well-matched related or unrelated donor 1
3. Conditioning: Must ablate expanded bone marrow; modern protocols achieve excellent results 1, 2

Standard Medical Management for Non-Transplant Candidates

Transfusion Protocol

Maintain pre-transfusion hemoglobin ≥9-10 g/dL through regular transfusions every 2-4 weeks 3, 4. This suppresses ineffective erythropoiesis, prevents skeletal deformities, and enables normal growth and development.

• Use leukoreduced, phenotypically matched red blood cells to minimize alloimmunization 4
• Target post-transfusion hemoglobin of 13-14 g/dL 3

Iron Chelation Therapy

Initiate iron chelation when serum ferritin exceeds 1000 ng/mL or after 10-20 transfusions 5. Iron overload causes cardiac failure, cirrhosis, diabetes, and endocrine dysfunction—the leading causes of death in non-transplanted patients.

Three chelation options:

• Deferasirox (oral, once daily)—most convenient
• Deferiprone (oral, three times daily)—superior cardiac iron removal
• Deferoxamine (subcutaneous/IV infusion)—gold standard efficacy

Monitor iron burden:

• Serum ferritin every 3 months (target <1000 ng/mL) 5
• Cardiac and hepatic MRI T2* annually to assess organ iron 5
• Adjust chelation intensity based on organ iron, not just ferritin

Critical Pitfall

Ferritin alone underestimates cardiac iron—patients can develop fatal cardiac failure with "acceptable" ferritin levels. MRI T2* is mandatory for cardiac assessment 5.

Emerging Disease-Modifying Therapies

For patients ineligible for HSCT, newer agents target the pathophysiology:

Luspatercept

Approved for transfusion-dependent β-thalassemia—reduces transfusion burden by improving ineffective erythropoiesis 6, 7. Consider in patients requiring high transfusion volumes despite optimal management.

Gene Therapy

First successful cases reported; now in clinical trials 1, 6. Represents future curative option for patients lacking suitable donors, though currently limited to specialized centers in industrialized countries.

Hydroxyurea

May reduce transfusion requirements in select patients with residual hemoglobin F production 6, 7. Trial in non-transfusion-dependent thalassemia or as bridge therapy.

Non-Transfusion-Dependent Thalassemia (NTDT)

Avoid regular transfusions unless complications develop: growth failure, skeletal deformities, extramedullary hematopoiesis, pulmonary hypertension, or leg ulcers 6.

• Monitor for iron overload even without transfusions—increased GI iron absorption causes accumulation 5
• Consider hydroxyurea or luspatercept to boost hemoglobin 6, 7
• Initiate chelation if ferritin >800 ng/mL or liver iron concentration elevated 5

Monitoring for Complications

Systematic surveillance prevents morbidity and mortality:

• Cardiac: Annual echocardiogram and MRI T2*; arrhythmia screening
• Endocrine: Annual glucose tolerance test, thyroid function, growth parameters, pubertal development; bone density every 2 years
• Hepatic: Liver function tests every 3 months; annual ultrasound and elastography; hepatitis B/C screening
• Infectious: Vaccinate against encapsulated organisms if splenectomized; screen for transfusion-transmitted infections

Special Populations

Pregnancy

Pre-conception counseling mandatory—assess cardiac function, optimize iron chelation (discontinue deferiprone/deferasirox, switch to deferoxamine if needed), ensure partner carrier testing 6.

Splenectomy

Reserve for patients with hypersplenism causing excessive transfusion requirements (>200-220 mL/kg/year of packed RBCs). Perform after age 5 years; ensure vaccination against S. pneumoniae, H. influenzae, N. meningitidis before surgery 6.

Prevention and Screening

Population carrier screening and genetic counseling reduce disease burden 6. In high-prevalence regions, offer:

• Premarital/preconception carrier screening
• Prenatal diagnosis for at-risk couples
• Genetic counseling regarding reproductive options

Algorithm Summary

1. Diagnosis confirmed → Assess transfusion dependence
2. Transfusion-dependent → HLA typing of patient and siblings immediately
3. HLA-matched donor available → Proceed to HSCT as soon as possible (age <14 years optimal)
4. No matched donor → Regular transfusions + iron chelation + consider gene therapy trials
5. Non-transfusion-dependent → Monitor closely; treat complications; consider hydroxyurea/luspatercept

The fundamental principle: HSCT before age 14 and before iron-related organ damage offers 96% disease-free survival and represents the only widely available cure 1. For those without donors, meticulous transfusion and chelation therapy enables survival into the 4th-5th decade 1, with emerging therapies offering hope for reduced disease burden 6, 7.